GlassScriptPhysician profile
James Luetkemeyer
NPI 1871643494
$4,907.93
in general payments reported to CMS, 2019-2025
30 companies · $808 in 2025
The $808 reported for 2025 was more than what 86% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $485 · 2020: $295 · 2021: $759 · 2022: $785 · 2023: $987 · 2024: $788 · 2025: $808.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,551 · Honoraria: $32.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,550.63 |
| Honoraria | $32.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $977.83 | 2019-2025 | Hydrus Microstent, Argos, Clareon |
| Abbvie INC. | $358.02 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $354.94 | 2019-2025 | |
| Allergan, INC. | $343.61 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $298.34 | 2022-2025 | Xiidra, Miebo, Akreos Ao Iol |
| Regeneron Healthcare Solutions, INC. | $286.15 | 2022-2025 | Eylea Hd |
| Johnson & Johnson Surgical Vision, INC. | $267.96 | 2021-2025 | Tecnis Iol, Catalys System, Tecnis Iol |
| Rxsight INC | $261.26 | 2023-2025 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Glaukos Corporation | $259.73 | 2021-2024 | Istent Trabecular Micro-Bypass System Model Is3 |
| Ivantis, INC | $240.47 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $183.01 | 2021-2024 | Acthar |
| Tarsus Pharmaceuticals, INC. | $145.53 | 2024-2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $132.91 | 2020-2023 | |
| Biogen, INC. | $115.70 | 2022-2023 | |
| Oyster Point Pharma, INC. | $100.48 | 2022-2023 | Tyrvaya |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $87.71 | 2022-2024 | Vabysmo |
| Thea Pharma INC. | $83.86 | 2023-2025 | Iyuzeh |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $76.89 | 2021 | |
| Aerie Pharmaceuticals, INC. | $47.04 | 2020-2021 | |
| Eyevance Pharmaceuticals LLC | $36.13 | 2022 | |
| Johnson & Johnson Vision Care, INC. | $33.49 | 2022-2024 | |
| Sight Sciences, INC. | $32.47 | 2020-2021 | |
| Dompe US, INC. | $30.23 | 2024 | Oxervate |
| Ocular Therapeutix, INC. | $29.70 | 2024-2025 | Dextenza |
| Kala Pharmaceuticals, INC. | $29.29 | 2020 | |
| Polarityte, INC. | $23.54 | 2019 | |
| Rayner Intraocular Lenses Limited | $19.86 | 2024 | Rayone Spheric, Rayone Aspheric, Rayone Emv |
| Horizon Therapeutics Plc | $19.04 | 2023 | Tepezza |
| Novo Nordisk INC | $17.65 | 2022 | |
| Apellis Pharmaceuticals, INC. | $15.09 | 2024 | Syfovre |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Luetkemeyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.